Drug Profile
Research programme: siRNA cancer therapeutics - Biothorpe
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Biothorpe Pharmaceuticals
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia
Highest Development Phases
- No development reported Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (Parenteral)